Comparison · NCT03271021-63fdd3a6
FMX101, 4% Minocycline Foam vs Vehicle Foam: Investigator Global Assessment (IGA) Treatment Success (Dichotomized as Yes/no) at Week 12, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. FMX101, 4% Minocycline Foam vs Vehicle Foam: Investigator Global Assessment (IGA) Treatment Success (Dichotomized as Yes/no) at Week 12, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline. Trial comparisons, record NCT03271021-63fdd3a6. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03271021-63fdd3a6
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.27 | 0.239 | 0.303 | wilson | |
| Risk in group 2 | 0.177 | 0.152 | 0.206 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0923 | 0.0501 | 0.134 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.52 | 1.25 | 1.85 | log | |
| Odds ratio, group 1 over group 2 | 1.71 | 1.34 | 2.19 | log | |
| Number needed to treat, for one more participant with the outcome on FMX101, 4% Minocycline Foam than on Vehicle Foam | 10.8 | 7.45 | 20 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: vehicle.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | FMX101, 4% Minocycline Foam | FMX101, 4% minocycline foam applied topically once daily for 12 weeks~FMX101: FMX101, 4% minocycline foam | 199 | 738 | OG000 |
| Group 2 | Vehicle Foam | Vehicle foam applied topically once daily for 12 weeks~Vehicle Foam: Vehicle Foam | 133 | 750 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
Investigator Global Assessment (IGA) Treatment Success (Dichotomized as Yes/no) at Week 12, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline
- Description
- Time frame
- 12 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris
- NCT number
- NCT03271021
- Phases
- PHASE3
- Conditions
- Acne Vulgaris
- Interventions
- FMX101, Vehicle Foam
- Lead sponsor
- Vyne Therapeutics Inc.
- Results first posted
- 2020-02-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03271021?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03271021-63fdd3a6